FORM	4
------	---

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

. Name and Address of Reporting Person 2. Issuer Name and Ticker or Trading Symbol SELICK HAROLD E THRESHOLD PHARMACEUTICALS INC [THLD] [THLD]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <u>X</u> Director <u>X</u> Officer (give title below) Other (specify below) Chief Executive Officer					
(Last) C/O THRESHOLD PHARMACEUT INC., 1300 SEAPORT BLVD SUITE	ICALS,	3. Date of Earliest Transaction (Month/Day/Year) 08/29/2008									
(Street) REDWOOD CITY, CA 94063		4. If Amendment, Date Original Filed(Month/Day/Year) 09/03/2008						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if any	3. Transaction Code4. Securities Acquired (A) or Disposed of (D) (Instr. 8)(Instr. 8)(Instr. 3, 4 and 5)			sposed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) Ownership Form:			
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock	08/29/2008		P <mark>(3)</mark>		49,019	А	\$ 2.04	239,480 (1) (2)	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code	tion)	5. Numbo of Deriva Securitie: Acquired or Dispos of (D) (Instr. 3, and 5)	tive s (A) sed	6. Date Exercisable and Expiration Date (Month/Day/Year) A)		6. Date Exercisable and Expiration Date (Month/Day/Year)		r) Title and Amount of Underlying Securities		Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial
				Code	V	(A)		Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(1130.4)			
Warrant for Common Stock	\$ 2.34	08/29/2008		P <u>(3)</u>		19,607		08/29/2008	08/29/2013	Common Stock	19,607	\$ 0	19,607	D			

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
SELICK HAROLD E C/O THRESHOLD PHARMACEUTICALS, INC. 1300 SEAPORT BLVD SUITE 500 REDWOOD CITY, CA 94063	Х		Chief Executive Officer					

Signatures

Harold E. Selick by Joel A. Fernandes, Attorney-In-Fact	09/05/2008
-Signature of Reporting Person	Date

Explanation of Responses:

^{*} If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) On August 18, 2008, a 1-for-6 reverse stock split of the issuer's common stock went into effect, resulting in a decrease in the reporting person's holdings as previously reported.
- (2) Includes 416 shares acquired under the Issuer's Employee Stock Purchase Plan on August 14, 2008
- (3) Acquired from the issuer pursuant to a Securities Purchase Agreement dated July 9, 2008

Remarks:

Amendment filed to correct Column 5 which erroneously indicated disposition of shares. The transaction was an acquisition of shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.